GlassScriptPhysician profile
William Blane Richardson
NPI 1215000468
$5,776.88
in general payments reported to CMS, 2019-2025
25 companies · $271 in 2025
The $271 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $981 · 2020: $118 · 2021: $567 · 2022: $1,707 · 2023: $745 · 2024: $1,387 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,695 · Travel and Lodging: $709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,694.51 |
| Travel and Lodging | $709.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,235.53 | 2019-2025 | Intracept, Wavewriter Alpha Prime 16, General - Pain Management |
| Spinal Simplicity, LLC | $1,476.79 | 2022-2025 | Ha Minuteman G3-R |
| Abbott Laboratories | $978.72 | 2019-2025 | Octrode, Proclaim, Eterna |
| Vertos Medical, INC. | $258.35 | 2021-2024 | Mild Device Kit |
| Electronic Waveform Lab, INC. | $98.75 | 2023 | |
| Grt US Holding, INC. | $83.00 | 2021 | |
| Nevro Corp. | $81.48 | 2019 | |
| Painteq LLC | $72.63 | 2023-2024 | Painteq |
| Saluda Medical Americas, INC. | $65.07 | 2022-2023 | Evoke Scs |
| Sentynl Therapeutics, INC. | $49.46 | 2019 | |
| Medtronic USA, INC. | $44.97 | 2019 | |
| Integra Lifesciences Corporation | $43.96 | 2019 | |
| Almatica Pharma LLC | $41.42 | 2021-2022 | |
| Merz North America, INC. | $35.20 | 2023 | |
| Curonix LLC | $34.83 | 2023-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zyla Life Sciences, INC. | $24.72 | 2019 | |
| Bioventus LLC | $24.04 | 2022 | |
| Revance Therapeutics, INC. | $21.95 | 2024 | Daxxify |
| Virtus Pharmaceuticals LLC | $21.24 | 2023 | Levorphanol Tartrate |
| Orthofix Medical, INC. | $17.59 | 2019 | |
| Organogenesis INC. | $16.04 | 2021 | |
| Medtronic, INC. | $15.54 | 2023 | Intellis Adaptivestim |
| Flowonix Medical Incorporated | $12.77 | 2019 | |
| Vertiflex, INC. | $12.35 | 2019 | |
| Nalu Medical, INC. | $10.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Richardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.